Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Equity Ratio (2017 - 2025)

Historic Equity Ratio for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to 0.78.

  • Vistagen Therapeutics' Equity Ratio fell 1093.71% to 0.78 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.78, marking a year-over-year decrease of 1093.71%. This contributed to the annual value of 0.83 for FY2025, which is 970.08% down from last year.
  • Latest data reveals that Vistagen Therapeutics reported Equity Ratio of 0.78 as of Q4 2025, which was down 1093.71% from 0.82 recorded in Q3 2025.
  • Over the past 5 years, Vistagen Therapeutics' Equity Ratio peaked at 0.94 during Q4 2023, and registered a low of 0.46 during Q2 2023.
  • Moreover, its 5-year median value for Equity Ratio was 0.83 (2025), whereas its average is 0.81.
  • As far as peak fluctuations go, Vistagen Therapeutics' Equity Ratio surged by 28528.37% in 2021, and later plummeted by 4189.94% in 2023.
  • Quarter analysis of 5 years shows Vistagen Therapeutics' Equity Ratio stood at 0.88 in 2021, then dropped by 21.22% to 0.7 in 2022, then soared by 35.16% to 0.94 in 2023, then fell by 6.57% to 0.88 in 2024, then dropped by 10.94% to 0.78 in 2025.
  • Its Equity Ratio stands at 0.78 for Q4 2025, versus 0.82 for Q3 2025 and 0.82 for Q2 2025.